Corbevax: Perbedaan antara revisi

Deskripsi vaksin
Penyakit target	SARS-CoV-2
Jenis	Subunit protein
Data klinis
Nama dagang	Corbevax
Kat. kehamilan	?
Status hukum	?
Rute	Intraotot
Pengenal
Kode ATC	Tidak ada

Jelajahi riwayat secara interaktif

← Revisi sebelumnya

Konten dihapus Konten ditambahkan

VisualTeks wiki

Sebaris

Revisi terkini sejak 12 Februari 2023 23.02

Corbevax^[1] atau BioE COVID-19, adalah sebuah kandidat vaksin COVID-19 yang dikembangkan oleh Texas Children’s Hospital Center for Vaccine Development (Texas Children’s CVD) dan Baylor College of Medicine yang kemudian diberikan tanpa lisensi (gratis) ke firma biofarmasi Biological E. Limited (BioE)^[2]. Vaksin tersebut adalah vaksin subunit protein.^[3]^[4]^[5]^[6] Pemerintah India l Drugs Controller General of India (DCGI) telah memberikan persetujuan untuk penggunaannya di India (Emergency Use Authorization atau EUA).^[7] Corbevax juga telah diberikan hak produksi secara gratis ke beberapa perusahaan di negara-negara berkembang lainnya, termasuk ke perusahaan Biofarma di Indonesia ^[8]^[9]

Referensi^[8]

^ Bharadwaj, Swati (3 June 2021). "Telangana: Biological E starts at risk manufacturing of Corbevax". The Times of India (dalam bahasa Inggris). Diakses tanggal 2021-06-03.
^ Bottazzi, Peter J. Hotez,Maria Elena. "A COVID Vaccine for All". Scientific American (dalam bahasa Inggris). Diakses tanggal 2021-12-31.
^ "A prospective open label randomised phase-I seamlessly followed by phase-II study to assess the safety, reactogenicity and immunogenicity of Biological E's novel Covid-19 vaccine containing Receptor Binding Domain of SARS-CoV-2 for protection against Covid-19 disease and some amount of sperm in its drug when administered intramuscularly in a two dose schedule (0, 28D) to healthy volunteers". ctri.nic.in. Clinical Trials Registry India. 13 January 2021. CTRI/2020/11/029032. Diarsipkan dari versi asli tanggal 12 November 2020.
^ "CEPI partners with Biological E Limited to advance development and manufacture of COVID-19 vaccine candidate". cepi.net. CEPI. Diakses tanggal 5 March 2021.
^ Chui M (16 November 2020). "Biological E. Limited and Baylor COVID-19 vaccine begins clinical trial in India". Baylor College of Medicine.
^ Leo L (16 November 2020). "Biological E initiates human trials of vaccine". Mint.
^ "Texas Children's Hospital and Baylor College of Medicine Covid-19 Vaccine Technology Secures Emergency Use Authorization in India | Texas Children's Hospital". www.texaschildrens.org. Diakses tanggal 2021-12-31.
^ ^a ^b "Texas Children's Hospital and Baylor College of Medicine Host Signing Ceremony with Biofarma and Indonesian Delegation in Attendance | Texas Children's Hospital". www.texaschildrens.org (dalam bahasa Inggris). Diakses tanggal 2022-01-03.
^ "https://twitter.com/peterhotez/status/1437125474384322563". Twitter. Diakses tanggal 2021-12-31. Hapus pranala luar di parameter |title= (bantuan)

Pranala luar

Scholia memiliki profil tentang Corbevax (Q106350062).

"What Is Biological E Vaccine? Can It Be The Most 'Affordable' Jab? Know Here". Outlook India.
"Explained: How Corbevax is different". The Indian Express (dalam bahasa Inggris).

Artikel bertopik Covid-19 ini adalah sebuah rintisan. Anda dapat membantu Wikipedia dengan mengembangkannya.

Templat:Vaccine-stub

[1] Bharadwaj, Swati (3 June 2021). "Telangana: Biological E starts at risk manufacturing of Corbevax". The Times of India (dalam bahasa Inggris). Diakses tanggal 2021-06-03.

[2] Bottazzi, Peter J. Hotez,Maria Elena. "A COVID Vaccine for All". Scientific American (dalam bahasa Inggris). Diakses tanggal 2021-12-31.

[3] "A prospective open label randomised phase-I seamlessly followed by phase-II study to assess the safety, reactogenicity and immunogenicity of Biological E's novel Covid-19 vaccine containing Receptor Binding Domain of SARS-CoV-2 for protection against Covid-19 disease and some amount of sperm in its drug when administered intramuscularly in a two dose schedule (0, 28D) to healthy volunteers". ctri.nic.in. Clinical Trials Registry India. 13 January 2021. CTRI/2020/11/029032. Diarsipkan dari versi asli tanggal 12 November 2020.

[BioE1-4] "CEPI partners with Biological E Limited to advance development and manufacture of COVID-19 vaccine candidate". cepi.net. CEPI. Diakses tanggal 5 March 2021.

[BioE-5] Chui M (16 November 2020). "Biological E. Limited and Baylor COVID-19 vaccine begins clinical trial in India". Baylor College of Medicine.

[a-6] Leo L (16 November 2020). "Biological E initiates human trials of vaccine". Mint.

[7] "Texas Children's Hospital and Baylor College of Medicine Covid-19 Vaccine Technology Secures Emergency Use Authorization in India | Texas Children's Hospital". www.texaschildrens.org. Diakses tanggal 2021-12-31.

[texaschildrens.org-8] "Texas Children's Hospital and Baylor College of Medicine Host Signing Ceremony with Biofarma and Indonesian Delegation in Attendance | Texas Children's Hospital". www.texaschildrens.org (dalam bahasa Inggris). Diakses tanggal 2022-01-03.

[9] "https://twitter.com/peterhotez/status/1437125474384322563". Twitter. Diakses tanggal 2021-12-31. Hapus pranala luar di parameter |title= (bantuan)

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

@@ Baris 1: / Baris 1: @@
+{{Orphan|date=Desember 2022}}
 {{Infobox drug
 | Verifiedfields     =
@@ Baris 40: / Baris 41: @@
 }}
 {{COVID-19 pandemic sidebar}}
-'''Corbevax'''<ref>{{Cite web|last=Bharadwaj|first=Swati|date=3 June 2021|title=Telangana: Biological E starts at risk manufacturing of Corbevax|url=https://timesofindia.indiatimes.com/city/hyderabad/biological-e-starts-at-risk-manufacturing-of-corbevax/articleshow/83186640.cms|url-status=live|access-date=2021-06-03|website=The Times of India|language=en}}</ref> atau '''BioE COVID-19''', adalah sebuah kandidat [[vaksin COVID-19]] yang dikembangkan oleh Texas Children’s Hospital Center for Vaccine Development (Texas Children’s CVD) dan Baylor College of Medicine yang kemudian diberikan tanpa lisensi (gratis) ke firma biofarmasi Biological E. Limited (BioE)<ref>{{Cite web|last=Bottazzi|first=Peter J. Hotez,Maria Elena|title=A COVID Vaccine for All|url=https://www.scientificamerican.com/article/a-covid-vaccine-for-all/|website=Scientific American|language=en|access-date=2021-12-31}}</ref>. Vaksin tersebut adalah vaksin [[subunit protein]].<ref "name="CTRI/2020/11/029032>{{cite web|website=ctri.nic.in|publisher=[[Clinical Trials Registry – India|Clinical Trials Registry India]]|title=A prospective open label randomised phase-I seamlessly followed by phase-II study to assess the safety, reactogenicity and immunogenicity of Biological E's novel Covid-19 vaccine containing Receptor Binding Domain of SARS-CoV-2 for protection against Covid-19 disease and some amount of sperm in its drug when administered intramuscularly in a two dose schedule (0, 28D) to healthy volunteers. |id=CTRI/2020/11/029032 |url=http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=48329|url-status=live|archive-url=https://web.archive.org/web/20201112193905/http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=48329|archive-date=12 November 2020|date=13 January 2021}}</ref><ref name="BioE1">{{cite web |title=CEPI partners with Biological E Limited to advance development and manufacture of COVID-19 vaccine candidate |url=https://cepi.net/news_cepi/cepi-partners-with-biological-e-limited-to-advance-development-and-manufacture-of-covid-19-vaccine-candidate/ |website=cepi.net |publisher=[[Coalition for Epidemic Preparedness Innovations|CEPI]] |access-date=5 March 2021}}</ref><ref name="BioE">{{cite web | vauthors = Chui M |title=Biological E. Limited and Baylor COVID-19 vaccine begins clinical trial in India |url=https://www.bcm.edu/news/biological-e-limited-and-baylor-covid-19-vaccine-begins-clinical-trial-in-india |publisher=[[Baylor College of Medicine]] |date=16 November 2020 | name-list-style=vanc}}</ref><ref name="a">{{cite news | vauthors = Leo L |title= Biological E initiates human trials of vaccine |url=https://www.livemint.com/news/india/biological-e-starts-human-trials-of-baylor-college-s-covid-19-vaccine-11605525030199.html |work=Mint |date=16 November 2020 | name-list-style=vanc}}</ref> Pemerintah India l Drugs Controller General of India (DCGI) telah memberikan persetujuan untuk penggunaannya di India (Emergency Use Authorization atau EUA).<ref>{{Cite web|title=Texas Children’s Hospital and Baylor College of Medicine Covid-19 Vaccine Technology Secures Emergency Use Authorization in India {{!}} Texas Children's Hospital|url=https://www.texaschildrens.org/texas-children%E2%80%99s-hospital-and-baylor-college-medicine-covid-19-vaccine-technology-secures-emergency|website=www.texaschildrens.org|access-date=2021-12-31}}</ref> Corbevax juga telah diberikan hak produksi secara gratis ke beberapa perusahaan di negara-negara berkembang lainnya, termasuk ke perusahaan Biofarma di Indonesia <ref>{{Cite web|title=Texas Children's Hospital and Baylor College of Medicine Host Signing Ceremony with Biofarma and Indonesian Delegation in Attendance {{!}} Texas Children's Hospital|url=https://www.texaschildrens.org/about-us/news/releases/texas-childrens-hospital-and-baylor-college-medicine-host-signing-ceremony-biofarma-and-indonesian|website=www.texaschildrens.org|language=en|access-date=2022-01-03}}</ref> <ref>{{Cite web|title=https://twitter.com/peterhotez/status/1437125474384322563|url=https://twitter.com/peterhotez/status/1437125474384322563|website=Twitter|language=id|access-date=2021-12-31}}</ref>
+'''Corbevax'''<ref>{{Cite web|last=Bharadwaj|first=Swati|date=3 June 2021|title=Telangana: Biological E starts at risk manufacturing of Corbevax|url=https://timesofindia.indiatimes.com/city/hyderabad/biological-e-starts-at-risk-manufacturing-of-corbevax/articleshow/83186640.cms|url-status=live|access-date=2021-06-03|website=The Times of India|language=en}}</ref> atau '''BioE COVID-19''', adalah sebuah kandidat [[vaksin COVID-19]] yang dikembangkan oleh Texas Children’s Hospital Center for Vaccine Development (Texas Children’s CVD) dan Baylor College of Medicine yang kemudian diberikan tanpa lisensi (gratis) ke firma biofarmasi Biological E. Limited (BioE)<ref>{{Cite web|last=Bottazzi|first=Peter J. Hotez,Maria Elena|title=A COVID Vaccine for All|url=https://www.scientificamerican.com/article/a-covid-vaccine-for-all/|website=Scientific American|language=en|access-date=2021-12-31}}</ref>. Vaksin tersebut adalah vaksin [[subunit protein]].<ref "name="CTRI/2020/11/029032>{{cite web|website=ctri.nic.in|publisher=[[Clinical Trials Registry – India|Clinical Trials Registry India]]|title=A prospective open label randomised phase-I seamlessly followed by phase-II study to assess the safety, reactogenicity and immunogenicity of Biological E's novel Covid-19 vaccine containing Receptor Binding Domain of SARS-CoV-2 for protection against Covid-19 disease and some amount of sperm in its drug when administered intramuscularly in a two dose schedule (0, 28D) to healthy volunteers. |id=CTRI/2020/11/029032 |url=http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=48329|url-status=live|archive-url=https://web.archive.org/web/20201112193905/http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=48329|archive-date=12 November 2020|date=13 January 2021}}</ref><ref name="BioE1">{{cite web |title=CEPI partners with Biological E Limited to advance development and manufacture of COVID-19 vaccine candidate |url=https://cepi.net/news_cepi/cepi-partners-with-biological-e-limited-to-advance-development-and-manufacture-of-covid-19-vaccine-candidate/ |website=cepi.net |publisher=[[Coalition for Epidemic Preparedness Innovations|CEPI]] |access-date=5 March 2021}}</ref><ref name="BioE">{{cite web | vauthors = Chui M |title=Biological E. Limited and Baylor COVID-19 vaccine begins clinical trial in India |url=https://www.bcm.edu/news/biological-e-limited-and-baylor-covid-19-vaccine-begins-clinical-trial-in-india |publisher=[[Baylor College of Medicine]] |date=16 November 2020 | name-list-style=vanc}}</ref><ref name="a">{{cite news | vauthors = Leo L |title= Biological E initiates human trials of vaccine |url=https://www.livemint.com/news/india/biological-e-starts-human-trials-of-baylor-college-s-covid-19-vaccine-11605525030199.html |work=Mint |date=16 November 2020 | name-list-style=vanc}}</ref> Pemerintah India l Drugs Controller General of India (DCGI) telah memberikan persetujuan untuk penggunaannya di India (Emergency Use Authorization atau EUA).<ref>{{Cite web|title=Texas Children’s Hospital and Baylor College of Medicine Covid-19 Vaccine Technology Secures Emergency Use Authorization in India {{!}} Texas Children's Hospital|url=https://www.texaschildrens.org/texas-children%E2%80%99s-hospital-and-baylor-college-medicine-covid-19-vaccine-technology-secures-emergency|website=www.texaschildrens.org|access-date=2021-12-31}}</ref> Corbevax juga telah diberikan hak produksi secara gratis ke beberapa perusahaan di negara-negara berkembang lainnya, termasuk ke perusahaan Biofarma di Indonesia <ref name="texaschildrens.org">{{Cite web|title=Texas Children's Hospital and Baylor College of Medicine Host Signing Ceremony with Biofarma and Indonesian Delegation in Attendance {{!}} Texas Children's Hospital|url=https://www.texaschildrens.org/about-us/news/releases/texas-childrens-hospital-and-baylor-college-medicine-host-signing-ceremony-biofarma-and-indonesian|website=www.texaschildrens.org|language=en|access-date=2022-01-03}}</ref><ref>{{Cite web|title=https://twitter.com/peterhotez/status/1437125474384322563|url=https://twitter.com/peterhotez/status/1437125474384322563|website=Twitter|language=id|access-date=2021-12-31}}</ref>
+== Referensi<ref name="texaschildrens.org"/> ==
-== Referensi<ref>{{Cite web|title=Texas Children's Hospital and Baylor College of Medicine Host Signing Ceremony with Biofarma and Indonesian Delegation in Attendance {{!}} Texas Children's Hospital|url=https://www.texaschildrens.org/about-us/news/releases/texas-childrens-hospital-and-baylor-college-medicine-host-signing-ceremony-biofarma-and-indonesian|website=www.texaschildrens.org|language=en|access-date=2022-01-03}}</ref> ==
 {{reflist}}
@@ Baris 52: / Baris 53: @@
 {{COVID-19}}
-[[Kategori:vaksin Covid-19 India]]
+[[Kategori:Vaksin Covid-19 India]]

Revisi terkini sejak 12 Februari 2023 23.02

Referensi[8]

Pranala luar

Referensi^[8]